[go: up one dir, main page]

WO2024086566A3 - Pan-sarbecovirus neutralizing antibodies and methods of use thereof - Google Patents

Pan-sarbecovirus neutralizing antibodies and methods of use thereof Download PDF

Info

Publication number
WO2024086566A3
WO2024086566A3 PCT/US2023/077073 US2023077073W WO2024086566A3 WO 2024086566 A3 WO2024086566 A3 WO 2024086566A3 US 2023077073 W US2023077073 W US 2023077073W WO 2024086566 A3 WO2024086566 A3 WO 2024086566A3
Authority
WO
WIPO (PCT)
Prior art keywords
sarbecovirus
pan
methods
neutralizing antibodies
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/077073
Other languages
French (fr)
Other versions
WO2024086566A2 (en
Inventor
Bali Pulendran
Yupeng Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2024086566A2 publication Critical patent/WO2024086566A2/en
Publication of WO2024086566A3 publication Critical patent/WO2024086566A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided herein are antibodies and antigen binding fragments that are capable of binding to a betacoronavirus, e.g. a sarbecovirus selected from one or more of SARS-CoV-2, SARS-CoV-2 omicron, SARS-CoV-2 beta, SARS-CoV-1, WIV-1, RaTG13, and SCH014.
PCT/US2023/077073 2022-10-19 2023-10-17 Pan-sarbecovirus neutralizing antibodies and methods of use thereof Ceased WO2024086566A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263380204P 2022-10-19 2022-10-19
US63/380,204 2022-10-19

Publications (2)

Publication Number Publication Date
WO2024086566A2 WO2024086566A2 (en) 2024-04-25
WO2024086566A3 true WO2024086566A3 (en) 2024-06-06

Family

ID=90738478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/077073 Ceased WO2024086566A2 (en) 2022-10-19 2023-10-17 Pan-sarbecovirus neutralizing antibodies and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2024086566A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152732A1 (en) * 2014-11-28 2016-06-02 The Israel Institute of Biological Research (IIBR) Antibodies directed to ricin toxin
US20190127458A1 (en) * 2017-11-01 2019-05-02 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
WO2021211775A1 (en) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2022153212A1 (en) * 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152732A1 (en) * 2014-11-28 2016-06-02 The Israel Institute of Biological Research (IIBR) Antibodies directed to ricin toxin
US20190127458A1 (en) * 2017-11-01 2019-05-02 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
WO2021211775A1 (en) * 2020-04-14 2021-10-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2022153212A1 (en) * 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FENG YUPENG, YUAN MENG, POWERS JOHN M., HU MENGYUN, MUNT JENNIFER E., ARUNACHALAM PRABHU S., LEIST SARAH R., BELLUSCI LORENZA, KIM: "Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 15, no. 695, 10 May 2023 (2023-05-10), XP093180664, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.adg7404 *

Also Published As

Publication number Publication date
WO2024086566A2 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
EP4257611A3 (en) Anti-muc1 antibody
SA519402358B1 (en) Anti-ccr7 antibody drug conjugates
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
WO2021231237A3 (en) Antibodies for sars-cov-2 and uses thereof
WO2020065330A3 (en) Chimeric antigen receptor
CA3254017A1 (en) Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2020123662A3 (en) Fusion protein constructs for complement associated disease
MX2020011588A (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom.
CR20230581A (en) Anti-ccr8 antibodies and uses thereof
EP4406555A3 (en) Antibodies to pmel17 and conjugates thereof
MX2025002472A (en) Anti-c5 antibody combinations and uses thereof
PH12021553197A1 (en) Anti-cd47 antibodies and uses thereof
CA3245580A1 (en) Novel anti-cd3 antibodies and uses thereof
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
MX2024015072A (en) Anti-egfr/met antibodies and uses thereof
WO2021067628A3 (en) Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
MX2025001452A (en) Anti-ccr8 antibodies and methods of use
WO2024086566A3 (en) Pan-sarbecovirus neutralizing antibodies and methods of use thereof
EP4274852A4 (en) Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
WO2021254574A3 (en) Cd38 antibodies for the treatment of human diseases
WO2021011673A3 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
WO2023196598A3 (en) Anti-mica/b antibodies and uses thereof
WO2023114701A3 (en) Cd28 binding antibodies and antigen binding fragments thereof
WO2025179048A3 (en) Antibodies that bind dach1 and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23880708

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23880708

Country of ref document: EP

Kind code of ref document: A2